^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

gevokizumab (VPM087)

i
Other names: VPM087, XOMA 052, XMA005.2, XOMA 052 Mab, XOMA-052, S-78989, XMA 005.2, XMA 052, S 78989, VPM 087
Associations
Company:
Novartis, Xoma
Drug class:
IL-1β inhibitor
Associations
over1year
Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis. (PubMed, Oncol Lett)
Most of the adverse reactions were mild and the rate of 3/4 grade TEAE was 10.37% (95% CI, 6.14-14.60%). Gevokizumab was effective and safe in the treatment of patients with advanced dMMR/MSI-H solid tumors and its convenience could significantly improve patient compliance; therefore, the clinical application of envafolimab is promising.
Retrospective data • Journal • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Enweida (envafolimab) • gevokizumab (VPM087)
over1year
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=168, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2025 --> Oct 2024
Trial completion date
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
almost2years
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=167, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
2years
Enrollment change • Trial withdrawal • Circulating tumor DNA
|
Signatera™
|
gevokizumab (VPM087)
over2years
Trial completion date • Trial primary completion date • Enrollment open • Circulating tumor DNA
|
Signatera™
|
gevokizumab (VPM087)
over2years
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Jan 2023
Trial completion date • Trial primary completion date • Combination therapy
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
over2years
NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. (ASCO 2022)
If ≥9 of 31 pts (29%) are alive and recurrence-free at 12 mos, then gevokizumab will be considered promising for further study. Enrollment continues towards the primary endpoint.
P2 data • Clinical • Tumor mutational burden • Circulating tumor DNA
|
TMB (Tumor Mutational Burden) • IL1B (Interleukin 1, beta)
|
Signatera™
|
gevokizumab (VPM087)
over2years
Trial completion date • Trial primary completion date • Circulating tumor DNA
|
Signatera™
|
gevokizumab (VPM087)
almost3years
New P2 trial • Clinical • Circulating tumor DNA
|
Signatera™
|
gevokizumab (VPM087)
3years
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Oct 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
over3years
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jan 2023 --> Jun 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
almost5years
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: May 2022 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CRP (C-reactive protein)
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)